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Antimicrobial peptides (AMPs) are components of innate immunity found in many forms of life. 30 
However, there have been no reports of AMPs in sea star (Phylum Echinodermata). Here we report 31 
the isolation and characterization of a novel antimicrobial peptide from the coelomic epithelium 32 
extract of the sea star Patiria pectinifera. The isolated peptide comprises 38 amino acid residues, is 33 
cationic (pI 9.2), has four cysteine residues that form two disulfide bonds (C1-C3 and C2-C4), is 34 
amidated at the C-terminus, and is designated P. pectinifera cysteine-rich antimicrobial peptide 35 
(PpCrAMP). Synthetic PpCrAMP identical to the native peptide exhibited the most potent 36 
antimicrobial activity compared to analogs with different disulfide bond configurations. Expression 37 
analysis of PpCrAMP precursor transcripts revealed constitutive expression in the coelomic 38 
epithelium and tube feet of P. pectinifera. Analysis of genomic DNA and cDNA encoding the 39 
PpCrAMP precursor protein revealed that an intron splits the coding region of the mature peptide into 40 
a positively charged N-terminal domain and a C-terminal domain harboring four cysteine residues and 41 
a glycine for C-terminal amidation. No significant homology with other known AMPs was observed, 42 
while orthologs of PpCrAMP were found in other echinoderm species. These findings indicate that 43 
PpCrAMP is the prototype of a family a novel cysteine-rich AMPs that participate in mechanisms of 44 
innate immunity in echinoderms. Furthermore, the discovery of PpCrAMP may lead to the 45 
identification of related AMPs in vertebrates and protostome invertebrates.  46 
 47 
Keywords: sea star, Patiria pectinifera, cysteine-rich antimicrobial peptide, innate immunity, 48 
echinoderm  49 
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1. Introduction 50 
Antimicrobial peptides (AMPs) are evolutionarily ancient molecules produced by a wide variety 51 
of organisms (Ganz, 2003; Zasloff, 2002). AMPs are a major component of the immune defense 52 
system in invertebrates, which lack a vertebrate-type adaptive immune system (Bulet et al., 2004; 53 
Sperstad et al., 2011). Although AMPs exhibit structural diversity, they are commonly defined as 54 
being short (10-50 amino acids, AAs) with a net positive charge (+2 to +9) and have been classified 55 
into three major groups: (i) linear peptides that form amphipathic α-helices, (ii) cysteine-rich peptides 56 
containing one or more disulfide bonds and (iii) peptides with an overrepresentation of one or two 57 
AAs (Bulet et al., 2004; Hancock and Lehrer, 1998; Wang et al., 2016; Zasloff, 2002). The peptides 58 
are derived from larger precursor proteins (prepropeptides) that consist of a signal peptide, a 59 
prosequence, and a mature peptide (Bulet et al., 2004; Liu and Ganz, 1995; Valore and Ganz, 1992). 60 
AMPs are not only characterized by direct antibiotic, antifungal, and antiviral activity against a 61 
variety of microorganisms but are also involved indirectly in modulation of the innate immunity, 62 
including induction of chemokine production and regulation of apoptosis, angiogenesis, and wound 63 
healing (Bowdish et al., 2005; Ganz, 2003; Guilhelmelli et al., 2013; Hancock and Sahl, 2006; 64 
Oppenheim and Yang, 2005). Because of the development of antibiotic resistance by microorganisms, 65 
AMPs have attracted considerable attention in recent years as potential anti-infective therapeutic 66 
candidates for the design of new antimicrobial agents (Craik et al., 2013; Gordon et al., 2005; 67 
Parachin and Franco, 2014). In this context, isolation of new AMPs is of interest in providing general 68 
insights into AMP structure and activity.  69 
Marine organisms live in habitats abundant with bacteria, fungi, viruses, and parasites, some of 70 
which are potentially harmful. However, many marine organisms do not seem to be vulnerable to 71 
pathogenic invasions, suggesting that they have robust and effective immune effectors such as AMPs 72 
to defend against microbial pathogens (Cheung et al., 2015; Falanga et al., 2016; Otero-Gonzalez et 73 
al., 2010). Furthermore, AMPs from marine organisms are often taxon-specific or even species-74 
specific and are structurally different from their counterparts produced by terrestrial species (Augustin 75 
et al., 2009; Charlet et al., 1996; Lee et al., 1997; Li et al., 2010b; Li et al., 2008; Smith et al., 2008). 76 
Therefore, marine organisms provide fascinating sources for biochemical isolation of novel AMPs.  77 
Echinoderms are a phylum of exclusively marine invertebrates that include sea star, sea urchins, 78 
sand dollars, sea cucumbers, and sea lilies. As deuterostome invertebrates, they occupy an 79 
intermediate phylogenetic position with respect to the vertebrates and protostome invertebrates and 80 
therefore they are of particular interest from an evolutionary perspective (Blair and Hedges, 2005; 81 
Smith et al., 2010). Echinoderms rely on innate immunity for defense against harmful microorganisms 82 
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and although they are the second largest deuterostome phylum, relatively few AMPs have been 83 
isolated and characterized from these animals. Cysteine-rich AMPs (strongylocins) isolated from the 84 
sea urchins Strongylocentrotus droebachiensis, Strongylocentrotus purpuratus, and Echinus 85 
esculentus (Li et al., 2010a; Li et al., 2008; Solstad et al., 2016) and heterodimeric AMPs (centrocins) 86 
isolated from S. purpuratus and E. esculentus (Li et al., 2010b; Solstad et al., 2016) exhibit 87 
antimicrobial activity against both gram-positive and gram-negative bacteria (Li et al., 2010a; Li et 88 
al., 2010b). Strongylocins and centrocins have unique structural characteristics compared to other 89 
known AMPs and therefore it is of interest to identify AMPs in other echinoderms (e.g. sea star). 90 
Here we report the isolation of a novel sea star cysteine-rich AMP, named PpCrAMP, from the 91 
sea star Patiria pectinifera. The primary structure of PpCrAMP was determined by Edman 92 
degradation and MALDI-TOF MS and the cysteine connectivity of four cysteine residues that form 93 
two disulfide bonds in PpCrAMP was determined by comparison of native and synthetic peptides that 94 
were produced with different combinations of two disulfide bond pairings. The antimicrobial activity 95 
of synthetic PpCrAMP variants was showed both gram-positive and gram-negative bacteria.  96 
Genomic DNA and cDNA encoding the PpCrAMP precursor protein were cloned and sequenced, 97 
enabling investigation of its expression pattern in P. pectinifera. Furthermore, the organization of the 98 
PpCrAMP gene in P. pectinifera was compared with homologs in other echinoderms. Discovery of 99 
PpCrAMP is notable as it is the first cysteine-rich AMP to be purified from sea star.       100 
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2. Materials and Methods 101 
2.1. Animals and sample collection 102 
 Specimens of the sea star Patiria pectinifera were collected at low tide from the intertidal 103 
zone on the rocky coast of Cheongsapo of Busan, Korea. The sea star were immediately transferred to 104 
our laboratory and maintained in a recirculating seawater system at 15 oC until sample collection. The 105 
coelomic epithelium, which includes layers of longitudinal and circular muscle, was collected from 106 
the aboral body wall of the arms of 100 specimens of P. pectinifera using sterile knives and forceps. 107 
The collected sample were immediately frozen in liquid nitrogen and stored at -80 °C until extraction. 108 
For immune challenge experiments, 30 live specimens of the sea star (approximate size 4-5 cm 109 
determined by the distance from the center of disk to outer tip of arm) were acclimatized in a 600 L 110 
recirculating aquarium tank equipped with sand-filtered and UV-sterilized seawater at 15 oC for 1 111 
month. The sea star were fed once every 3 days with live manila clam, Ruditapes philippinarum.  112 
Approval by the local institution/ethics committee was not required for this work because 113 
experimental work on sea star is not subject to regulation and P. pectinifera is not an endangered or 114 
protected species. 115 
2.2. Peptide extraction and purification 116 
Four volumes of 1% acetic acid was added to the frozen sample and then the mixture was 117 
heated in a double boiler for 5 min to prevent proteolytic enzyme activity. The boiled sample was 118 
cooled on ice and homogenized (T10 basic ULTRA-TURRAX Homogenizer system, IKA, USA). The 119 
homogenate was then centrifuged (20,000 × g, 30 min, 4 oC) and then the supernatant was applied 120 
onto a C18 cartridge (Sep-pak C18, 20 cc, Waters Corp, USA). The column was washed with 40 ml of 121 
10% methanol/0.1% trifluoroacetic acid (TFA) and retained materials were then eluted with 40 ml of 122 
60% methanol/0.1% TFA. An aliquot of the eluate was lyophilized and then dissolved in 0.01% acetic 123 
acid to evaluate its antimicrobial activity against Escherichia coli D31 and Bacillus subtilis 124 
KCTC1021. To purify antimicrobial components of the eluate, a portion (3 ml) of it was applied to a 125 
cation-exchange column (TSKgel SP-5PW, 7.5 × 75 mm, Tosho, Japan) and eluted with a linear 126 
gradient of 0 to 1.0 M sodium chloride in 10 mM phosphate buffer (PB, pH 6.0) for 100 min at a flow 127 
rate of 1.0 ml/min. Absorbance peaks were monitored at 220 nm to detect peptide bonds and fractions 128 
were collected manually. A bioactive peak from the first cation-exchange HPLC purification was 129 
subjected to reversed phase (RP)-HPLC (Capcellpak C18, 5μm, 4.6 × 250 mm; Shisheido Co., Tokyo, 130 
Japan). Elution was performed by isocratic elution in 10% acetonitrile/0.1% TFA for 10 min and then 131 
a linear gradient of 10 to 60% acetonitrile/0.1% TFA for 50 min at a flow rate of 1.0 ml/min. An 132 
active peak showing antimicrobial activity against B. subtilis KCTC 1021 was purified by 133 
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chromatography again using the same column as the previous step, but with isocratic elution in 22% 134 
acetonitrile/0.1% TFA (peak A) at a flow rate of 1 ml/min. 135 
2.3. Primary structure determination of the purified peptide 136 
The molecular mass and AA sequence of the purified AMP were determined using matrix 137 
assisted laser desorption/ionization (MALDI) time-of-flight (TOF) mass spectrometry (MS) with a 138 
pulsed smartbeam II (355 nm Nd:YAG laser, repetition rate 1 kHz) in linear mode (Ultraflextreme 139 
from Bruker Daltonics, Billerica, MA, USA) and an automated N-terminal AA gas-phase sequencer 140 
(PPSQ-31A/33A protein sequencers, Shimadzu Co., Kyoto, Japan). To confirm the existence of 141 
disulfide bonds, the purified peptide was reduced with 100 μl of 0.1 M 1,4-dithiothreitol (DTT) 142 
solution for 2 h at 42 °C. After reduction of disulfide bonds, the retention times of the reduced and the 143 
native peptides were compared using RP-HPLC with a linear gradient of 5 - 65% acetonitrile/0.1% 144 
TFA for 60 min at a flow rate of 1 ml/min.  145 
2.4. Peptide synthesis and determination of disulfide bridge connectivity 146 
Based on the results of structure analyses and cDNA cloning, variants of PpCrAMP with three 147 
possible disulfide bond connectivities were custom synthesized by ChemPep Inc. (Wellington, FL, 148 
USA). The synthetic peptides were re-purified to be greater than 98% pure by RP-HPLC, and 149 
molecular masses were confirmed by MALDI-TOF MS. The reduced form of the synthetic peptide 150 
was obtained by RP-HPLC purification followed by the same procedure used for native PpCrAMP. 151 
The molecular mass of the reduced synthetic PpCrAMP was also confirmed by MALDI-TOF MS 152 
with observation of a 4 mass unit difference. Identity was assessed by comparison of the retention 153 
times of synthetic peptides and native PpCrAMP using RP-HPLC with a linear gradient of 20 to 30% 154 
acetonitrile/0.1% TFA for 20 min and, then, an isocratic elution with 23% acetonitrile/0.1% TFA. The 155 
quantities of the purified synthetic peptides were calculated using a linear relationship between peak 156 
area and peptide amount in a serial dilution of 1 mg/ml of synthetic PpCrAMP. 157 
2.5. Antimicrobial activity assay 158 
An ultrasensitive radial diffusion assay was adopted for monitoring antimicrobial activity 159 
during the purification steps and for testing synthetic peptides, as described previously (Seo et al., 160 
2016). The microbial strains used to evaluate the antimicrobial activity were B. subtilis KCTC1021, 161 
Staphylococcus aureus KCTC1621, Micrococcus luteus KCTC1071, E. coli D31, Streptococcus iniae 162 
FP5229, Salmonella enterica ATCC13311, Shigella flexneri KCTC2517, Aeromonas hydrophila 163 
KCTC2358, Edwardsiella tarda NUF251, and Vibrio parahaemolyticus KCCM41664, and Candida 164 
albicans KCTC9765 (Table 1). Briefly, microbial strains were pre-cultured overnight in tryptic soy 165 
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broth (TSB) at the appropriate temperatures, 25 °C for fish pathogens and 37 °C for the others. Pre-166 
cultured microbial strains were diluted with 10 mM PB (pH 6.6) to ~108 CFU/ml for microbial strains 167 
and ~106 CFU/ml for the fungus C. albicans, and 0.5 ml of the diluted strains was mixed with 9.5 ml 168 
of underlay gel containing 0.03% TSB and 1% Type I agarose in10 mM PB (pH 6.6). Peptides were 169 
serially diluted 2-fold in 5 μl of 0.01% acetic acid and each dilution was added to 2.5 mm diameter 170 
wells made in the 1 mm thick underlay gels. After 3 h of incubation at the appropriate temperatures, 171 
microbial strains were overlaid with 10 ml of double-strength overlay gel containing 6% TSB with 172 
10 mM PB (pH 6.6) in 1% agarose. Plates were incubated for an additional 18 - 24 h and then the 173 
clear zone diameters were measured. After subtracting the diameter of the well, the clear zone 174 
diameter was expressed in units (0.1 mm = 1 U). The minimal effective concentration (MEC, μg/ml) 175 
of the synthetic peptides was calculated as the X-intercept of a plot of units against the log10 of the 176 
peptide concentration (Lehrer et al., 1991). The antimicrobial assay was performed in triplicate and 177 
the results were averaged. 178 
2.6. cDNA and gene cloning 179 
Cloning of a cDNA encoding the complete PpCrAMP precursor protein was performed by 3’ 180 
and 5’ rapid amplification of cDNA ends (RACE) polymerase chain reaction (PCR). Total RNA was 181 
extracted from the coelomic epithelium of P. pectinifera using Hybrid-R kit (GeneAll, Seoul, Korea), 182 
and then mRNA was purified using Oligotex mRNA mini kit (Qiagen, USA) following the 183 
manufacturer’s instructions. The synthesis for RACE-ready cDNA template was performed with 184 
GeneRacer kit (RLM-RACE, Invitrogen, CA, USA) according to the manufacturer’s instructions. The 185 
sequence of primers for 3’RACE was based on analysis of a GenBank transcriptome shotgun 186 
assembly (TSA) database (accession no. GFOQ01277783.1) from P. pectinifera obtained by Illumina 187 
HiSeq 2500 sequencing, reported previously by our group (Kim et al., 2017). Two sequence specific 188 
primers were designed for 3’ RACE, and then 5’ RACE was conducted with sequence-specific 189 
primers designed from the sequencing result of the 3’ RACE product. The sequences of primers used 190 
in RACE are listed in Table 1. The first 3’RACE reaction (30 cycles, 95 °C for 30 s, 60°C for 30 s, 191 
and 72 °C for 1 min) was performed using a primer (GSP-F1) and the GeneRacer 3′ primer. The PCR 192 
product was re-amplified (30 cycles, 95 °C for 30 s, 58°C for 30 s, and 72 °C for 1 min) using a 193 
primer (GSP-F2) and GeneRacer 3′ nested primer. The 5’ RACE reaction (30 cycles, 95 °C for 30 s, 194 
58°C for 30 s, and 72 °C for 1 min) was completed using a gene-specific primer (GSP-R) and the 195 
GeneRacer 5′ primer. PCR products in the last step of 3’ and 5’ RACE were introduced into the 196 
pGEM-Teasy vector system (Promega Corporation, USA) and sequenced. The sequence of precursor 197 
transcripts obtained was submitted to the GenBank database (accession no. MF443207).  198 
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Based on the cDNA sequence of the PpCrAMP precursor, both forward (Gene F) and reverse 199 
(Gene R) primers located in the 5’ and 3’ untranslated regions (UTRs) of the cDNA sequence were 200 
designed for studying the gene structure (see Table S1 for sequences). Genomic DNA was extracted 201 
from the coelomic epithelium of one animal using Exgene DNA extraction kit (GeneAll, Seoul, 202 
Korea) following the manufacturer’s instructions and 100 ng of genomic DNA was employed as a 203 
template in PCR (30 cycles, 95 °C for 30 s, 58°C for 30 s, and 72 °C for 3 min). The PCR product 204 
was also cloned into pGEM-Teasy vector and sequenced. The sequence of genomic DNA containing 205 
the PpCrAMP gene was also submitted to the GenBank database (accession no. MF443208). 206 
2.7. Real time quantitative polymerase chain reaction (RT-qPCR) of PpCrAMP precursor transcripts 207 
RT-qPCR analysis was done to determine the basal expression level of PpCrAMP precursor 208 
transcripts in various tissues, including coelomic epithelium, coelomocytes, gonad, oral hemal ring 209 
including Tiedemann’s bodies, pyloric caeca, stomach (including cardiac and pyloric regions), and 210 
tube feet. Furthermore, to determine whether acute changes in the abundance of PpCrAMP precursor 211 
transcripts occur following immune stimulation, tissues that express PpCrAMP constitutively 212 
(coelomic epithelium and tube feet) were sampled 0, 8, 16, and 32 h post-immune stimulation. The 213 
immune challenge was performed by injection with 50 μl V. parahaemolyticus (OD600=0.1, 3.3×108 214 
CFU/ml) into the coelomic cavity through the body wall at the tip of each of the arms of sea star with 215 
arm lengths of 4-5 cm. Total RNA was extracted from pooled sample tissues (five individuals per 216 
pool) using Hybrid-R (GeneAll, Seoul, Korea) according to the manufacturer's instructions, and RNA 217 
quality was assessed by 1.0% agarose gel electrophoresis and then quantified spectrophotometrically 218 
using a NanoDrop Lite (Thermo Fisher Scientific, Wilmington, MA, USA). cDNA was synthesized 219 
using the TOPscript cDNA synthesis Kit with oligo dT (dT18) (Enzynomics, Deajeon, Korea) 220 
according to the manufacturer's instructions. The primer pairs used for amplifying PpCrAMP 221 
precursor cDNA and elongation factor 1α (EF1α, accession No. AAT06175) cDNA as a control for 222 
normalization were PpCrAMP qPCR-F and qPCR-R, and EF1α qPCR-F and qPCR-R, respectively 223 
(see Table S1 for sequences). To analyze expression of PpCrAMP precursor transcripts in different sea 224 
star tissues/organs quantitatively, RT-qPCR was employed using a CFX Connect Real-Time PCR 225 
Detection System (Bio-Rad, USA), as previously described with slight modifications (Kim et al., 226 
2016). In brief, the amplification was carried out in a 20 μl reaction mixture containing 10 μl of 2× 227 
SYBR green premix (TOPreal qPCR 2X PreMix, Enzynomics, Deajeon, Korea), 1 μl (10 pmol/μl) 228 
each of forward and reverse primers, 1 μl of 10 times diluted cDNA template and nuclease free water. 229 
The thermal profile was 95 °C for 10 min, 40 cycles of 95 °C for 10 s, 60 °C for 15 s and 72 °C for 15 230 
s with fluorescence recording at the end of each cycle. Melt curve analysis was performed to ensure 231 
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product specificity over the temperature range of 60-90 °C. Amplicons were analyzed on agarose gels 232 
to confirm the product size. Based on the standard curves for both PpCrAMP and EF1α, the relative 233 
expression levels of PpCrAMP precursor transcripts in each tissue were normalized against the level 234 
of the EF1α control using the comparative CT method (2-ΔΔCT) (Livak and Schmittgen, 2001). 235 
Triplicate amplifications were carried out independently, and the results were analyzed statistically. 236 
For statistical analysis of PpCrAMP precursor transcript expression, the graphs were generated, and 237 
one-way analysis of variance (ANOVA) with Duncan's multiple range post-hoc analysis was 238 
performed using GraphPad Prism software version 7.0 for Windows (GraphPad Software, San Diego, 239 
California, USA). Relative fold expression was presented as means ± standard deviation. P values 240 
with p < 0.05 were considered statistically significant. 241 
2.8. In silico analysis 242 
A cDNA encoding the PpCrAMP precursor protein was translated into protein sequence using 243 
Expert Protein Analysis System (ExPASy) proteomics server of the Swiss Institute of Bioinfromatics 244 
(http://web.expasy.org/translate/) and SignalP 4.1 (http://www.cbs.dtu.dk/services/SignalP/) was used 245 
to predict the signal peptide of the translated protein sequence. Theoretical molecular mass and 246 
isoelectric points of the mature PpCrAMP were calculated by the computer pI/Mw tools 247 
(http://web.expasy.org/compute_pi/) at ExPASy. To identify potential homologs of PpCrAMP the 248 
deduced AA sequence and genomic nucleotide sequence of the PpCrAMP were submitted as queries 249 
for BLAST analysis of i) the NCBI/GenBank nr database (http://blast.ncbi.nlm.nih.gov/blast.cgi), ii) 250 
the AMP database, including the collection of antimicrobial peptides (CAMP, 251 
http://www.camp.bicnirrh.res.in), iii) the antimicrobial peptide database (APD, 252 
http://aps.unmc.edu/AP/main.php), iv) the Echinoderm genomic database 253 
(http://www.echinobase.org/Echinobase/Blasts) and v) neural transcriptome sequence data from the 254 
sea star Asterias rubens (Semmens et al., 2013; Semmens et al., 2016). Multiple sequence alignment 255 
of the full-length P. pectinifera PpCrAMP precursor and putative related proteins from other species 256 
was performed using a multiple sequence alignment algorithm, Kalign, from the European 257 
Bioinformatics Institute (EMBL-EBI) (https://www.ebi.ac.uk/Tools/msa/kalign/). Secondary structure 258 
prediction was performed using the Network Protein Sequence Analysis (NPS@: https://npsa-259 
prabi.ibcp.fr/) server (Combet et al., 2000).  260 
3. Results 261 
3.1. Purification of AMP from the coelomic epithelium of Patiria pectinifera 262 
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An aliquot of a coelomic epithelium extract of P. pectinifera exhibited antimicrobial activity 263 
against B. subtilis and E. coli, which was abolished by tryptic digestion (Fig. 1A), indicating that it 264 
was an appropriate source to isolate AMPs. The gram-positive bacterium B. subtilis was highly 265 
susceptible to the crude extract and so was used to test for antimicrobial activity during the 266 
purification steps. A single absorbance peak (peak A) that exhibited antimicrobial activity against B. 267 
subtilis was purified successfully from the coelomic epithelium extract through three steps of column 268 
purification. The extract was first fractionated using cation-exchange HPLC with a salt gradient and 269 
an active peak was eluted with 0.6 M sodium chloride corresponding to a retention time of 69 min 270 
(Fig. 1B). The peak was further subjected to RP-HPLC and an active peak, designated as peak A, was 271 
eluted with 22% acetonitrile/0.1% TFA (Fig. 1C). Finally, a single absorbance peak was obtained 272 
with isocratic 22% acetonitrile/0.1% TFA elution, and this peak was then subjected to structural 273 
analyses (Fig. 1D). 274 
3.2. Primary structure analyses of purified AMP 275 
The first 37 AAs from the N-terminus of the purified peptide were determined by Edman 276 
sequencing (Fig. 2A), but with some unidentified residues (X) from blank cycles. The molecular mass 277 
determined by MALDI-TOF MS was 4027.8 Da and 2014.7 as the protonated molecular ion (M+H)+ 278 
and the double charged ion (M+2H)2+, respectively (Fig. 2B upper panel). Without reduction and 279 
alkylation cysteine residues often emerge as blank cycles during amino acid sequencing because they 280 
form disulfide bonds that are important for the folding and stability of AMPs and proteins. Therefore, 281 
the purified AMP from P. pectinifera was reduced by treatment with DTT to confirm the existence of 282 
disulfide bonds. The retention time of the reduced peptide was revealed as 29.8 min, which 283 
represented a delay of about 2 min compared to the native form (Fig 2C), and the molecular mass of 284 
the reduced peptide was 4 Da higher than the native peptide (Fig. 2B lower panel). These data 285 
indicated that the purified native peptide contained four cysteine residues that formed two 286 
intramolecular disulfide bonds. Accordingly, in the deduced sequence of the AMP we replaced three 287 
X residues with cysteine residues and added an additional cysteine residue at the C-terminus: 288 
GRKGRKGVRGNPFFNCEDEFGNPGCVCDKRKGGAAVTC. This peptide was designated P. 289 
pectinifera cysteine-rich antimicrobial peptide (PpCrAMP). The theoretical molecular mass of the 290 
deduced peptide in reduced form was calculated as 4032.6 Da (M+H)+, which differed from observed 291 
molecular mass of reduced PpCrAMP by 1 Da (Fig. 2B lower panel). C-terminal amidation is a 292 
common post-translational modification of AMPs and this decreases the molecular mass by only 1 Da 293 
compared to peptides with a free carboxyl-terminus. Furthermore, glycine is a substrate for C-terminal 294 
amidation. To investigate if PpCrAMP was C-terminally amidated in this way, the AA sequence of 295 
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PpCrAMP was submitted as a query against the non-redundant protein sequences in the NCBI 296 
database using BLAST (https://blast.ncbi.nlm.nih.gov/Blast.cgi) but no significant sequence 297 
homology with other known AMPs was observed. Therefore, we attempted to find putative transcripts 298 
encoding PpCrAMP in GenBank transcriptome shotgun assemblies (TSA) of Patiria (taxid: 35076) 299 
using BLAST. Two transcripts were found that encoded proteins identical or similar to the AA 300 
sequence of PpCrAMP: a 1,242 bp transcribed RNA (accession No. GFOQ01277783.1) and a 910 bp 301 
transcribed RNA (accession No. GAWB01039446.1) from de novo assembled transcriptomes of P. 302 
pectinifera and P. miniata, respectively (Fig. 2D). The transcripts encoded PpCrAMP or a PpCrAMP-303 
like protein with a glycine residue at its C-terminus, consistent with this residue being a substrate for 304 
amidation mediated by peptidylglycine α-amidating monooxygenase (PAM) (Eipper et al., 1991) and 305 
the mature PpCrAMP peptide having an α-amide at the C-terminus. In conclusion, the structural 306 
analyses demonstrated that PpCrAMP was a C-terminally amidated cationic AMP (with a predicted 307 
isoelectric point (pI) of 9.20; http://web.expasy.org/compute_pi/) comprising 38 AAs, which include 308 
four cysteine residues (Cys16, Cys25, Cys27 and Cys38) that form two disulfide bonds (Fig. 2D). 309 
3.3.  Determination of cysteine connectivity in native PpCrAMP 310 
The four cysteine residues in PpCrAMP could mediate three different cysteine connectivities to 311 
form two intramolecular disulfide bonds. To determine the authentic cysteine connectivity in the 312 
native peptide, we synthesized C-terminally amidated PpCrAMPs that have the three different 313 
cysteine connectivities: PpCrAMP-1 (Cys16-Cys25 and Cys27-Cys38), PpCrAMP-2 (Cys16-Cys27 and 314 
Cys25-Cys38) and PpCrAMP-3 (Cys16-Cys38 and Cys25-Cys27) corresponding to C1-C2 and C3-C4, 315 
C1-C3 and C2-C4, and C1-C4 and C2-C3, respectively (Fig. 3A). The retention time of native 316 
PpCrAMP was compared with the elution times of the synthetic peptides using RP-HPLC. Native 317 
PpCrAMP was eluted at 15.1 min in a gradient elution, which was almost identical to the retention 318 
time (14.9 min) of synthetic PpCrAMP-2. In contrast, both synthetic PpCrAMP-1 and PpCrAMP-3 319 
and the reduced form of PpCrAMP (PpCrAMPreduced) were eluted at 16.6, 16.8 and 19.1 min on the 320 
same RP-HPLC, respectively, which represented delays of 2 to 4 min compared to the native peptide 321 
(Fig. 3B). Furthermore, native PpCrAMP and synthetic PpCrAMP-2 co-eluted with isocratic RP-322 
HPLC (Fig. 3C), whereas the retention times of both synthetic PpCrAMP-1 and PpCrAMP-3 were 323 
not identical to synthetic PpCrAMP-2 (Fig. 3D and E). Collectively, these findings indicated that the 324 
four cysteine residues in native PpCrAMP formed two disulfide bonds with Cys16-Cys27 and Cys25-325 
Cys38 pairings (i.e. C1-C3, C2-C4 connectivity) and the C-terminus of native PpCrAMP was 326 
amidated. 327 
3.4. Antimicrobial activity of synthetic PpCrAMP variants 328 
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All four synthetic PpCrAMP variants exhibited antimicrobial activity against the gram-negative 329 
bacteria S. enterica and S. flexneri, with a minimal effective concentration (MEC) of 4.5 to 330 
31.4 μg/ml, and against the gram-positive bacteria B. subtilis, S. aureus, and M. luteus, with a MEC of 331 
15.6 to >250 μg/ml. However, the antimicrobial activity of synthetic PpCrAMP-2 was significantly 332 
higher than the antimicrobial activity of the other synthetic PpCrAMPs and reduced PpCrAMP (Table 333 
1). The most potent antimicrobial activity exhibited by all four synthetic PpCrAMPs was against the 334 
gram-negative bacterium S. enterica [MECs, 4.5 – 8.4 μg/ml]. However, antimicrobial activity of 335 
synthetic PpCrAMPs was barely detectable against fish pathogens and was undetectable with the 336 
fungus C. albicans. These findings demonstrated that the existence of the disulfide bonds in 337 
PpCrAMP was not critical for antimicrobial activity, but the cysteine connectivity in native PpCrAMP 338 
corresponding to C1-C3 and C2-C4 was required for maximum activity against the bacteria tested 339 
here. Interestingly, while coelomic epithelium extract showed antimicrobial activity against E. coli 340 
D31 (Fig. 1A), all four synthetic PpCrAMPs did not show antimicrobial activity against E. coli D31 341 
up to a peptide concentration of 250 μg/ml, indicating that the coelomic epithelium extract also 342 
contained other AMPs responsible for antimicrobial activity against E. coli D31. 343 
3.5.  cDNA and genomic DNA sequence encoding PpCrAMP 344 
To obtain the complete sequence of the PpCrAMP precursor protein, a cDNA encoding 345 
PpCrAMP was cloned and sequenced (accession number: MF443207). The cDNA of the PpCrAMP 346 
precursor comprised 926 bp, starting with a 5’-UTR of 81 bp, followed by an open reading frame 347 
(ORF) of 240 bp, a 3’-UTR of 605 bp containing a polyadenylation consensus sequence (AATAAA) 348 
located at 31 bp upstream of a poly(A)+ tail (Fig. 4A). The deduced AA sequence of the ORF of the 349 
PpCrAMP precursor started with a signal peptide of 21 residues, as predicted by SignalP 4.1, 350 
followed by two peptide fragments cleaved at putative dibasic cleavage site (Lys39Arg40): an N-351 
terminal prosequence (Ser22-Val38) containing several anionic AAs and mature PpCrAMP consisting 352 
of 38 AAs plus one C-terminal glycine residue (Gly41-Gly79), consistent with the structural analyses 353 
(Fig. 4B). Accordingly, these sequence data demonstrated that PpCrAMP was derived from a larger 354 
precursor protein which underwent post-translational modifications such as formation of disulfide 355 
bonds and α-amidation at the C-terminus followed by cleavage at a putative dibasic cleavage site 356 
(KR) between the anionic prosequence and the mature peptide. The genomic DNA sequence encoding 357 
PpCrAMP (accession number: MF443208) comprised two exons and one intron (Fig. 4B). The first 358 
exon comprised a 5′ UTR followed by an ORF encoding the signal peptide, the prosequence, and the 359 
first 14 AAs of mature PpCrAMP, which was followed by an 896 bp intron. The second exon 360 
comprised an ORF encoding the cysteine-rich region of PpCrAMP (25 AAs) followed by a 3′ UTR. 361 
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The classical canonical splicing recognition sequence GT/AG was present at the exon-intron 362 
junctions. 363 
BLAST analysis revealed that PpCrAMP exhibited no significant sequence homology with other 364 
known AMP precursors. However, genomic DNA sequence encoding PpCrAMP exhibited sequence 365 
similarity with genes in the sea star P. miniata (accession No. AKZP01101613), the sea star 366 
Acanthaster planci (accession No. BDGH01001773), the sea cucumber P. parvimensis (accession No. 367 
JXUT0100825), and the sea urchin S. purpuratus (accession No. AAGJ05078965) (Fig. 5A). All four 368 
genes were similar to the P. pectinifera PpCrAMP gene in containing one intron and two exons, which 369 
encoded homologs of the PpCrAMP precursor. In addition, analysis of neural transcriptome sequence 370 
data from the sea star Asterias rubens (Semmens et al., 2013; Semmens et al., 2016) revealed two 371 
transcripts encoding homologs of the PpCrAMP precursor – ArCrAMP-1 precursor (accession 372 
number: MG711458) and ArCrAMP-2 precursor (accession number: MG711459). A multiple 373 
alignment of the PpCrAMP precursor with homologs identified in other echinoderms is shown in Fig. 374 
5B. The PpCrAMP precursor shared 96.2% AA identity with the homolog from the sea star P. 375 
miniata, 53.6% AA identity with the homolog from the sea star A. planci, 45.7% and 46.6% identity 376 
with the two homologs from the sea star A. rubens, 43.1% AA identity with the homolog from the sea 377 
urchin S. purpuratus, and 34.3% AA with the homolog from the sea cucumber P. parvimensis. 378 
Collectively, these data indicated that PpCrAMP was the prototype for a novel family of cysteine-rich 379 
AMPs that occur in echinoderms.  380 
 381 
3.6. RT-qPCR analysis for PpCrAMP mRNA 382 
To compare expression levels of PpCrAMP transcript in various sea star tissues and post immune 383 
challenge, the relative expression levels of the PpCrAMP precursor transcript in different tissues 384 
(coelomic epithelium, coelomocytes, gonad, oral hemal ring, pyloric caeca, stomach, and tube feet) of 385 
P. pectinifera were determined by RT-qPCR using sequence specific primers targeting the PpCrAMP 386 
coding region. An EF1α gene was used as an invariant control and for comparison of relative 387 
expression between transcripts (Kim et al., 2016). The results showed that the highest expression level 388 
of PpCrAMP precursor transcripts was detected in the tube feet and the coelomic epithelium, which 389 
was the original source of PpCrAMP in this study, followed by moderate expression levels in the oral 390 
hemal ring (including Tiedemann’s bodies), and the stomach (Fig. 6A). These findings indicated that 391 
the coelomic epithelium and the tube feet were the major tissues/organs that produced PpCrAMP in P. 392 
pectinifera. Accordingly, these two tissues were selected to determine whether acute changes in the 393 
abundance of PpCrAMP precursor transcript occur after bacterial challenge. However, no significant 394 
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changes in PpCrAMP precursor expression were observed at different times after the bacterial 395 
challenge (Fig. 6B). 396 
  397 
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4. Discussion 398 
Few AMPs have been identified in echinoderms to date. Strongylocins and centrocins were first 399 
isolated from coelomocytes of the green sea urchin (S. droebachiensis) and related peptides 400 
(SpStronylocins 1 and 2) were then discovered and characterized in the purple sea urchin 401 
(S. purpuratus) and the edible sea urchin (E. esculentus) (Li et al., 2010a; Li et al., 2010b; Li et al., 402 
2008; Solstad et al., 2016). These are cationic peptides that exhibit antimicrobial activity against both 403 
gram-positive and gram-negative bacteria (Li et al., 2010a; Li et al., 2008). Strongylocins with six 404 
cysteine residues forming three intramolecular disulfide bonds show a cysteine arrangement pattern 405 
different from any known cysteine-rich AMPs with six cysteine residues and have post-translational 406 
modifications such as a brominated tryptophan (Li et al., 2008). Centrocins have a heterodimeric 407 
structure, containing a heavy chain (30 AAs) and a light chain (12 AAs), and also have a brominated 408 
tryptophan (Li et al., 2010b). Thus, AMPs isolated from echinoderm species, including strongylocins 409 
and centrocins, have distinct structures compared to those that have been isolated from vertebrates and 410 
protostomes. Here we report the purification from an extract of the coeleomic epithelium of the sea 411 
star P. pectinifera of a novel AMP designated PpCrAMP, which contains four cysteine residues that 412 
form two disulfide bonds and which has a amidated C-terminal cysteine (Fig. 2 and 3).  413 
Cysteine-rich AMPs represent the most diverse and widely distributed family of AMPs in the 414 
animal kingdom. Depending on the number of cysteine residues (mostly between 2 to 8) and their 415 
paring, cysteine-rich AMPs are classified into three groups: a β-sheet conformation with triple strands, 416 
a β-hairpin-like structure, and a mixed α-helix/β-sheet conformation (Bulet et al., 2004). Among these 417 
three groups of peptides, AMPs containing four cysteine residues that form two disulfide bonds have 418 
been identified in arthropods and pigs (Fig. 7): tachyplesin and polypemusin from the horseshoe crab 419 
Tachypleus tridentatus and Limulus polyphemus (Miyata et al., 1989; Nakamura et al., 1988), 420 
respectively, gomesin from the spider Acanthoscuria gomesiana (Silva et al., 2000), androctonin from 421 
the scorpion Androctonus australis (Ehret-Sabatier et al., 1996), and protegrin from porcine 422 
leukocytes (Storici and Zanetti, 1993). Moreover, with exception of androctonin, all of these peptides 423 
are amidated at the C-terminus and their cysteine connectivity is C1-C4 and C2-C3 (Fahrner et al., 424 
1996; Laederach et al., 2002; Mandard et al., 2002). In contrast, the novel AMP identified here in the 425 
sea star P. pectinifera, PpCrAMP, has two disulfide bonds with C1-C3 and C2-C4 connectivity.  426 
The antimicrobial activity of synthetic PpCrAMP, with C1-C3 and C2-C4 cysteine connectivity 427 
(PpCrAMP-2), is identical to that of the native peptide, and synthetic PpCrAMP-2 exhibits the most 428 
potent activity against both gram-positive and gram-negative bacteria compared with other synthetic 429 
variants. Investigation of the importance of the disulfide bonds in cysteine-rich antimicrobial peptides 430 
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with two disulfide bonds demonstrates that the peptides require the correct disulfide bond 431 
configuration to adopt a conformation such as the β-hairpin-like structure and to retain full bioactivity 432 
(Laederach et al., 2002; Mani et al., 2005; Muhle and Tam, 2001; Rao, 1999). The β-hairpin-like 433 
structure consists of two antiparallel β-strands stabilized by a disulfide bond, linked by a short loop of 434 
two to five amino acids (Panteleev et al., 2015). The β-hairpin-like structure that is essential for the 435 
activity seen in cysteine-rich AMPs (e.g. tachyplesin-I and protegrin-I) is consistent with the predicted 436 
consensus secondary structure of PpCrAMP (Fig. 7). Analysis of the sequence of PpCrAMP using the 437 
NPS@ server indicates that PpCrAMP is likely to adopt a β-hairpin-like structure consisting of two 438 
extended β-strands (residues 25-28 and 35-37) linked by a random coil region. Therefore, the potent 439 
antimicrobial activity of synthetic PpCrAMP-2 may reflect the disulfide bond connectivity that 440 
establishes the most stable structure. Further investigation of the relationship between conformation 441 
and antimicrobial activity of PpCrAMP will be required to address this issue. Homologs of PpCrAMP 442 
identified in other echinoderms also have four cysteine residues in equivalent positions but C-terminal 443 
amidation appears not to be a generic characteristic. For example, the two PpCrAMP-type proteins 444 
identified in the sea star A. rubens do not have C-terminal glycine residue that could provide a 445 
substrate for C-terminal amidation.   446 
The PpCrAMP gene contains an intron that interrupts the region of the open reading frame 447 
encoding the mature PpCrAMP, with one exon encoding the N-terminal domain and another exon 448 
encoding the C-terminal domain that contains four cysteine residues. Orthologous genes in other 449 
echinoderm species, including the sea curcumber P. parvimensis and the sea urchin S. purpuratus, 450 
have the same intron/exon structure (Fig. 4 and 5). Although the organization of genes encoding 451 
cysteine-rich AMPs is very diverse, the peptides are classified in the same structural scaffold group 452 
based upon size, cysteine pattern and function, revealing links between the AMPs found in vertebrates 453 
and those found in invertebrates (Charlet et al., 1996; Froy, 2005). Nothing is known about the 454 
occurrence of PpCrAMP-like proteins in other phyla. However, the occurrence of PpCrAMP-type 455 
proteins in echinoderms, a phylum that occupies an “intermediate” position with respect to the 456 
deuterostome invertebrates, which include two chordate subphyla that are closely related to 457 
vertebrates and the Ambulacraria, and protostome invertebrates, indicates there is a possibility of the 458 
presence of orthologous genes and proteins related to defense in deuterostome invertebrates as well as 459 
protostomes.  460 
Analysis of the expression of the PpCrAMP precursor transcripts in P. pectinifera using qPCR 461 
reveals that the coelomic epithelium and the tube feet are a major source of PpCrAMP. This is  462 
consistent with our recent finding that the coelomic epithelium and the tube feet are grouped in a 463 
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tissue/organ cluster with a related biological functions based on an evaluation of differentially 464 
expressed genes in P. pectinifera using de novo transcriptome data (BioProject accession: 465 
PRJNA371229) (Kim et al., 2017). The coelomic epithelium is a tissue layer that lines the aboral 466 
inner surface of the body wall of sea star. It appears to be a unique tissue with many features of an 467 
“ancient multifunctional organogenetic tissue”, which is involved not only in common epithelial 468 
functions, but also in a range of important biological processes such as wound healing, regeneration, 469 
and haematopoiesis (Bossche and Jangoux, 1976; Holm et al., 2008). The absence of change in the 470 
expression levels of the PpCrAMP precursor transcripts after immune challenge suggests that 471 
PpCrAMP may contribute to innate immune defense in an indirect manner. Recent study on the 472 
neuropeptide NDA-1, which was secreted in sensory and ganglion of the ectodermal epithelium of the 473 
model organism Hydra during early development, surprisingly shows antimicrobial activity that may 474 
affect microbiome composition on the body surface (Augustin et al., 2017). PpCrAMP may also 475 
contribute to endocrine system with antimicrobial activity in a similar manner on the body surface.   476 
In conclusion, PpCrAMP, the cysteine-rich AMP isolated from the coelomic epithelium of the 477 
sea star P. pectinifera, is the first reported sea star AMP. This study increases our knowledge of AMPs 478 
that are involved in the innate immune system of sea star and other echinoderm species and may lead 479 
to the discovery of homologs that are involved in immune mechanisms of other animal types. 480 
Furthermore, PpCrAMP along with AMPs isolated from other echinoderms may provide a framework 481 
for development of novel antimicrobial drugs. 482 
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Figure legends 619 
Fig. 1. Isolation of an AMP from an extract of coelomic epithelium of the sea star P. pectinifera. (A) 620 
Antimicrobial activity of the crude and the trypsin treated extract against B. subtilis KCTC 1021 and 621 
E. coli D31 is shown. (B) Fractionation of the crude extract by cation-exchange HPLC reveals an 622 
active peak (downward arrow) is eluted with 0.6 M sodium chloride. (C). A single absorbance peak 623 
(peak A) responsible for the antimicrobial activity against B. subtilis was obtained in the second RP-624 
HPLC step. (D) Peak A was isolated through RP-HPLC with isocratic elution in 22% 625 
acetonitrile/0.1% TFA. 626 
Fig. 2. Primary structure determination of purified AMP. (A) N-terminal 37 amino acid residues of 627 
purified peak A was determined by Edman degradation. (B) The retention times of the native peptide 628 
and the reduced peptide (after treatment 0.1 M DTT) on RP-HPLC were compared. (C). MALDI-TOF 629 
MS analysis of the native peptide and the reduced peptide showed a 4 Da difference in molecular 630 
mass consistent with the presence of two disulfide bonds. (D). Complete primary structure of purified 631 
peak A designated P. pectinifera cysteine-rich AMP (PpCrAMP) comprised 38 AAs with C-terminal 632 
α-amidation and was compared with sequences derived from transcriptome data obtained from P. 633 
pectinifera and P. miniata. 634 
Fig. 3. Determination of the disulfide bond cysteine connectivity of native PpCrAMP (A) Structures 635 
of four PpCrAMP variants with three different disulfide bond connectivities or without disulfide 636 
bonds are shown. (B) The retention times of native PpCrAMP and synthetic variants were compared 637 
using RP-HPLC with a linear gradient of 20% to 30% acetonitrile/0.1% TFA over 20 min. (C) Native 638 
PpCrAMP co-elutes with synthetic PpCrAMP that has a C1-C3 and C2-C4 connectivity using RP-639 
HPLC under isocratic conditions with 23% acetonitrile/0.1% TFA. (D) Synthetic PpCrAMP-1 and 640 
PpCrAMP-3 co-elute under the same conditions as in (C). (E) Synthetic PpCrAMP-1 and PpCrAMP-641 
2 do not co-elute under the same conditions as in (C).  642 
Fig. 4. Sequence and structural features of the P. pectinifera PpCrAMP precursor. (A) Schematic 643 
showing the structure of a cDNA encoding the PpCrAMP precursor protein is shown. (B) DNA 644 
sequence of the gene encoding the PpCrAMP precursor protein, which comprises two exons (upper 645 
case) separated by an intron (lowercase) is shown. The canonical splicing recognition sequence 646 
GT/AG and the polyadenylation signal site are shadow boxed and underlined, respectively. The amino 647 
acid sequence of the precursor is shown below the coding sequence, with the predicted signal peptide, 648 
anionic prosequence and purified mature PpCrAMP shown in blue, black, and red, respectively, and a 649 
putative dibasic cleavage site (KR) shown in green. A glycine residue that provides a substrate for C-650 
terminal amidation is boxed and the stop codon is indicated with an asterisk. The sequences of the 651 
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cDNA and genomic DNA encoding the PpCrAMP precursor are accessible from GenBank under 652 
accession numbers MF443207 and MF443208, respectively. 653 
Fig. 5. Comparison of the gene structure and sequences of PpCrAMP-type proteins in echinoderms 654 
(A). The structure of the gene encoding PpCrAMP in the sea star P. pectinifera with related genes in 655 
the sea star P. miniata and A. planci, the sea cucumber P. parvimensis, and the sea urchin S are 656 
compared. purpuratus: (B) Sequence alignment of P. pectinifera PpCrAMP with PpCrAMP-like 657 
peptides from other echinoderms.   658 
Fig. 6. Quantitative analysis of basal expression of PpCrAMP precursor transcripts in various 659 
organs/tissues (A) and after immune challenge in the coelomic epithelium and the tube feet (B) from 660 
P. pectinifera. The relative expression levels of PpCrAMP transcripts in each organ/tissue were 661 
normalized against the level of the EF1α gene as an internal control. Means ± standard deviation 662 
(n=3) are shown. Means denoted by the same letter did not differ significantly (p > 0.05) while 663 
different letters (a, b, c, d) at the top of the bars indicate statistically significant differences (p < 0.05) 664 
between tissues determined by one-way ANOVA followed by Duncan’s Multiple Range test.  665 
Fig. 7. Comparison of amino acid sequence and cysteine array of P. pectinifera PpCrAMP to 666 
vertebrate and invertebrate cysteine-rich AMPs that have four cysteine residues forming two disulfide 667 
bonds and adopting β-hairpin-like structure. PpCrAMP is compared with (i) tachyplesin-I and (ii) 668 
polyphemusin-I from the horseshoe crabs T. tridentatus and L. polyphemus, respectively (Miyata et 669 
al., 1989; Nakamura et al., 1988); (iii) gomesin from the spider A. gomesiana (Silva et al., 2000); (iv) 670 
androctonin from the scorpion A. australis (Ehret-Sabatier et al., 1996); (v) protegrin from from 671 
porcine leukocytes (Storici and Zanetti, 1993). Lowercase (a) at the C-terminus of peptides and 672 
lowercase (p) at the N-terminus of peptides indicate a C-terminal α-amide and pyroglutamate, 673 
respectively. Predicted consensus secondary structure of PpCrAMP using NPS@ server is shown 674 
below the amino acid sequence. Lowercase c (orange) and e (blue) indicate random coil and extended 675 
strand, respectively.  676 
  677 
23 
 
Table legend 678 
Table 1. Antimicrobial activity against various microbial strains of synthetic PpCrAMPs, including 679 
the reduced peptide and peptides with three different combinations of two disulfide bonds   680 
24 
 
Supplementary table legend 681 
Supplementary Table S1. Designations and nucleotide sequences of the primers used in this study  682 
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Figure 2. 685 
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Table 1. Antimicrobial activity against various microbial strains using synthetic PpCrAMPs, including 698 
a reduced linear peptide and peptides with two disulfide bonds in three different configurations 699 
 Microbe 
aMinimal effective concentration (μg/ml) 
PpCrAMP-1 PpCrAMP-2 PpCrAMP-3 PpCrAMPred. 
Gram-positive     
Bacillus subtilis KCTC1021 33.8 22.9 38.3 42.3 
Staphylococcus aureus KCTC1621 32.1 15.6 41.2 91.2 
Micrococcus luteus KCTC1071 >250 153 >250 82.9 
Gram-negative     
Escherichia coli D31 bND ND ND ND 
Salmonella enterica ATCC13311 8.0 4.5 8.1 8.4 
Shigella flexneri KCTC2517 29.8 12.2 31.4 24.2 
Marine bacterium (gram-
positive) 
    
Streptococcus iniae FP5229 ND ND ND ND 
Marine bacteria (gram-
negative) 
    
Aeromonas hydrophila KCTC2358 ND 107.2 ND ND 
Edwardsiella tarda NUF251 ND ND ND ND 
Vibrio parahaemolyticus 
KCCM41664 
ND >250 ND ND 
Fungus     
Candida albicans KCTC9765 ND ND ND ND 
aAntimicrobial assay were performed in triplicates and the results were averaged. 700 
bND means not detected in the range of the concentrations tested up to 250 μg/ml of peptides  701 
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Supplementary Table S1. Designations and nucleotide sequences of the primers used in this study 702 
Primers Nucleotide sequence (5’→3’) Usage 
GSP-F1 GGTGTCAGGGGCAATCCTTT  
GSP-F2 CAACTGTGAAGACGAGTTCGG cDNA cloning 
GSP-R GCATGTACTTAGCCGCAGG  
Gene F AACTCGCCTCTCCGCAAAA 
Gene cloning Gene R ACTAGGCCAGATGTGAGCAG 
PpCrAMP qPCR-F GGTGTCAGGGGCAATCCTTT 
RT-qPCR 
PpCrAMP qPCR-R GGCTCCACCCTTCCTTTTGT 
EF1α qPCR-F TCAACGACTACCAGCCCCTA 





 A novel cysteine-rich AMP (PpCrAMP) is identified from the starfish Patiria pectinifera. 
 PpCrAMP adopts two disulfide bonds with Cys16-C27 and Cys25-Cys38 pairings. 
 PpCrAMP transcripts are highly expressed in the tube feet and the coelomic epithelium. 
 PpCrAMP gene contains an intron. 
 PpCrAMP exhibits antimicrobial activity to different bacteria. 
 
